ReviewImmunoTargets and therapy2021
Alopecia Areata: An Autoimmune Disease of Multiple Players.
Review in ImmunoTargets and therapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 64 citations in OpenAlex.
- Vitamin D deficiency in non-scarring and scarring alopecias: a systematic review and meta-analysis.Frontiers in nutrition · 2024Pooled it
- Platelet-rich plasma in alopecia areata and primary cicatricial alopecias: A systematic review.Frontiers in medicine · 2022Pooled it
- Efficacy and safety of ritlecitinib in Asian patients with alopecia areata: A subgroup analysis of the ALLEGRO phase 2b/3 trial.The Journal of dermatology · 2025Trial
- Leukotrichia: A comprehensive review of follicular depigmentation.The Journal of international medical research · 2026Review
- Exploring the potential of natural products in treating alopecia areata.Journal of pharmaceutical analysis · 2026Review
- Localized follicular delivery of a JAK inhibitor using optimized PhosGlyNanoVes: a novel approach for alopecia areata treatment.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Ruxolitinib reverses alopecia areata via a triple mechanism: JAK-STAT inhibition, localized oxidative stress attenuation and selective apoptosis modulation.Journal of translational autoimmunity · 2026Article
- Dental Rehabilitation of a Child Diagnosed With Alopecia Areata Totalis: A Case Report.Cureus · 2026Article
- ROS-responsive hydrogel-delivered miR-665 targets STAT3 to alleviate inflammation and promote hair follicle regeneration in alopecia areata.Journal of nanobiotechnology · 2026Article
- Crisaborole as a Potential Treatment for Pediatric Alopecia Areata: A Case Report and Literature Review.Cureus · 2026Article
- Efficacy of Janus Kinase Inhibitors in Alopecia in Jordanian Patients: A Retrospective Cohort Study.Cureus · 2025Article
- Modulating immune responses in alopecia: therapeutic insights and potential targets of antisense oligonucleotides.BMC immunology · 2025Review
- Assessment of miR-19b-3p, miR-182-5p, and miR-155-5p expression and its relation.Archives of dermatological research · 2025Article
- From Multiple Sclerosis to Organ-Specific Autoimmune Disorders: Insights into the Molecular and Clinical Implications of Comorbidity.Molecular neurobiology · 2025Review
- Investigating the Genetic Association of Selected Candidate Loci with Alopecia Areata Susceptibility in Jordanian Patients.Medicina (Kaunas, Lithuania) · 2025Article
- Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities.Cureus · 2025Review
- From mechanisms to therapies: current advances breakthroughs in alopecia areata immunopathology.Frontiers in immunology · 2025Review
- Impact of Previous Alopecia Areata Treatment on Efficacy Responses up to Week 48 Following Ritlecitinib Treatment: A Post Hoc Analysis.Dermatology and therapy · 2024Article
- Deciphering the Complex Immunopathogenesis of Alopecia Areata.International journal of molecular sciences · 2024Review
- Lichen Sclerosus of the Labial Mucosa: A Case Report and Literature Review.Clinical, cosmetic and investigational dermatology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alopecia areata (AA) is an autoimmune disease of the hair follicles. It is characterized by a well-defined non-scarring alopecic patch or patches that may extend to the entire scalp or lead to total body hair loss. Due to its unpredictable clinical course, AA causes substantial psychological harm. Despite the high prevalence of this disease and extensive research, its exact pathomechanism is unclear, and current treatments have a high relapse rate that has deemed AA incurable. Over the past few decades, researchers have investigated multiple potential factors that may help alleviate its pathogenesis and provide effective treatment. Given its complex immunopathogenesis, AA is considered an autoimmune disease with multiple factors. This review gathers current evidence that emphasizes molecular mechanisms, possible causative etiologies, and targeted immunotherapies for AA. Understanding its underlying mechanisms may shed light on new strategies to effectively manage AA in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.